262 related articles for article (PubMed ID: 32066906)
1. Programmable base editing of mutated TERT promoter inhibits brain tumour growth.
Li X; Qian X; Wang B; Xia Y; Zheng Y; Du L; Xu D; Xing D; DePinho RA; Lu Z
Nat Cell Biol; 2020 Mar; 22(3):282-288. PubMed ID: 32066906
[TBL] [Abstract][Full Text] [Related]
2. Base editing of the mutated TERT promoter inhibits liver tumor growth.
Zhao G; Ma Q; Yang H; Jiang H; Xu Q; Luo S; Meng Z; Liu J; Zhu L; Lin Q; Li M; Fang J; Ma L; Qiu W; Mao Z; Lu Z
Hepatology; 2024 Jun; 79(6):1310-1323. PubMed ID: 38016019
[TBL] [Abstract][Full Text] [Related]
3. Disruption of the β1L Isoform of GABP Reverses Glioblastoma Replicative Immortality in a TERT Promoter Mutation-Dependent Manner.
Mancini A; Xavier-Magalhães A; Woods WS; Nguyen KT; Amen AM; Hayes JL; Fellmann C; Gapinske M; McKinney AM; Hong C; Jones LE; Walsh KM; Bell RJA; Doudna JA; Costa BM; Song JS; Perez-Pinera P; Costello JF
Cancer Cell; 2018 Sep; 34(3):513-528.e8. PubMed ID: 30205050
[TBL] [Abstract][Full Text] [Related]
4. Cancer-specific loss of
Amen AM; Fellmann C; Soczek KM; Ren SM; Lew RJ; Knott GJ; Park JE; McKinney AM; Mancini A; Doudna JA; Costello JF
Proc Natl Acad Sci U S A; 2021 Mar; 118(13):. PubMed ID: 33758097
[TBL] [Abstract][Full Text] [Related]
5. Genome Editing Reveals Glioblastoma Addiction to MicroRNA-10b.
El Fatimy R; Subramanian S; Uhlmann EJ; Krichevsky AM
Mol Ther; 2017 Feb; 25(2):368-378. PubMed ID: 28153089
[TBL] [Abstract][Full Text] [Related]
6. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss.
Arita H; Narita Y; Fukushima S; Tateishi K; Matsushita Y; Yoshida A; Miyakita Y; Ohno M; Collins VP; Kawahara N; Shibui S; Ichimura K
Acta Neuropathol; 2013 Aug; 126(2):267-76. PubMed ID: 23764841
[TBL] [Abstract][Full Text] [Related]
7. Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis.
Spiegl-Kreinecker S; Lötsch D; Ghanim B; Pirker C; Mohr T; Laaber M; Weis S; Olschowski A; Webersinke G; Pichler J; Berger W
Neuro Oncol; 2015 Sep; 17(9):1231-40. PubMed ID: 25681309
[TBL] [Abstract][Full Text] [Related]
8. Targeting oncogenic TERT promoter variants by allele-specific epigenome editing.
Kouroukli AG; Rajaram N; Bashtrykov P; Kretzmer H; Siebert R; Jeltsch A; Bens S
Clin Epigenetics; 2023 Nov; 15(1):183. PubMed ID: 37993930
[TBL] [Abstract][Full Text] [Related]
9. Nrf2-driven TERT regulates pentose phosphate pathway in glioblastoma.
Ahmad F; Dixit D; Sharma V; Kumar A; Joshi SD; Sarkar C; Sen E
Cell Death Dis; 2016 May; 7(5):e2213. PubMed ID: 27148686
[TBL] [Abstract][Full Text] [Related]
10. CRISPR/Cas9-Mediated TERT Disruption in Cancer Cells.
Wen L; Zhao C; Song J; Ma L; Ruan J; Xia X; Chen YE; Zhang J; Ma PX; Xu J
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963842
[TBL] [Abstract][Full Text] [Related]
11. Cancer-associated TERT promoter mutations abrogate telomerase silencing.
Chiba K; Johnson JZ; Vogan JM; Wagner T; Boyle JM; Hockemeyer D
Elife; 2015 Jul; 4():. PubMed ID: 26194807
[TBL] [Abstract][Full Text] [Related]
12. A novel two-step genome editing strategy with CRISPR-Cas9 provides new insights into telomerase action and TERT gene expression.
Xi L; Schmidt JC; Zaug AJ; Ascarrunz DR; Cech TR
Genome Biol; 2015 Nov; 16():231. PubMed ID: 26553065
[TBL] [Abstract][Full Text] [Related]
13. Elevated TERT Expression in TERT-Wildtype Adult Diffuse Gliomas: Histological Evaluation with a Novel TERT-Specific Antibody.
Masui K; Komori T; Kato Y; Masutomi K; Ichimura K; Ogasawara S; Kaneko MK; Oki H; Suzuki H; Nitta M; Maruyama T; Muragaki Y; Kawamata T; Sawada T; Shibata N
Biomed Res Int; 2018; 2018():7945845. PubMed ID: 29693015
[TBL] [Abstract][Full Text] [Related]
14. New somatic TERT promoter variants enhance the Telomerase activity in Glioblastoma.
Pierini T; Nardelli C; Lema Fernandez AG; Pierini V; Pellanera F; Nofrini V; Gorello P; Moretti M; Arniani S; Roti G; Giovenali P; Lupattelli M; Metro G; Molica C; Castrioto C; Corinaldesi R; Laurenti ME; Ascani S; Mecucci C; La Starza R
Acta Neuropathol Commun; 2020 Aug; 8(1):145. PubMed ID: 32843091
[TBL] [Abstract][Full Text] [Related]
15. MRI Features Associated with TERT Promoter Mutation Status in Glioblastoma.
Ivanidze J; Lum M; Pisapia D; Magge R; Ramakrishna R; Kovanlikaya I; Fine HA; Chiang GC
J Neuroimaging; 2019 May; 29(3):357-363. PubMed ID: 30644143
[TBL] [Abstract][Full Text] [Related]
16. TERT promoter mutations in primary and secondary glioblastomas.
Nonoguchi N; Ohta T; Oh JE; Kim YH; Kleihues P; Ohgaki H
Acta Neuropathol; 2013 Dec; 126(6):931-7. PubMed ID: 23955565
[TBL] [Abstract][Full Text] [Related]
17. Telomerase inhibition is an effective therapeutic strategy in TERT promoter-mutant glioblastoma models with low tumor volume.
Aquilanti E; Kageler L; Watson J; Baird DM; Jones RE; Hodges M; Szegletes ZM; Doench JG; Strathdee CA; Figueroa JRMF; Ligon KL; Beck M; Wen PY; Meyerson M
Neuro Oncol; 2023 Jul; 25(7):1275-1285. PubMed ID: 36694348
[TBL] [Abstract][Full Text] [Related]
18. Argininosuccinate lyase drives activation of mutant TERT promoter in glioblastomas.
Shi Z; Ge X; Li M; Yin J; Wang X; Zhang J; Chen D; Li X; Wang X; Ji J; You Y; Qian X
Mol Cell; 2022 Oct; 82(20):3919-3931.e7. PubMed ID: 36270249
[TBL] [Abstract][Full Text] [Related]
19. High incidence of TERT mutation in brain tumor cell lines.
Johanns TM; Fu Y; Kobayashi DK; Mei Y; Dunn IF; Mao DD; Kim AH; Dunn GP
Brain Tumor Pathol; 2016 Jul; 33(3):222-7. PubMed ID: 26960334
[TBL] [Abstract][Full Text] [Related]
20. The TERT promoter mutation status and MGMT promoter methylation status, combined with dichotomized MRI-derived and clinical features, predict adult primary glioblastoma survival.
Shu C; Wang Q; Yan X; Wang J
Cancer Med; 2018 Aug; 7(8):3704-3712. PubMed ID: 29984907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
